ADAP and Hepatitis B Coverage  In June 2012, 29 ADAPs covered at least one of the medications for HBV on their formularies.  ADAPs filled 325 hepatitis.

Slides:



Advertisements
Similar presentations
Egyptian Guidelines For Management of Chronic Hepatitis B
Advertisements

HCV Assays: Impact on HCV Studies & Update on HCV blood bank protocol.
Hepatitis web study Hepatitis web study Simeprevir in Genotype 1 (Viral Relapsers) PROMISE Trial Phase 3 Treatment Experienced Forns X, et al. Gastroenterology.
4n + 6 A number increased by six times four A number plus six
HIV and Hepatitis B or C co-infection Preliminary results of survey.
?.
North Carolina AIDS Drug Assistance Program (ADAP) State Pharmaceutical Assistance Program (SPAP)
Appraising the 2014 AASLD and IDSA Guidelines on HCV Testing and Linkage to Care TARIK IBRAHIM ZAHER TARIK IBRAHIM ZAHER Professor of Tropical Medicine,
Prof. Fatma Amer Medical Microbiology and Immunology, ZAGAZIG FACULTY OF Medicine, Egypt President of ISC/HWG President of ArAPUA In the Era of Direct.
Andrew Hill, Liverpool University, UK World AIDS Conference, Melbourne, Australia, July 2014 Cost drivers for Hepatitis C treatments: options for lowering.
Hepatitis B workshop on Identifying Aims, Goals, Gaps, and Priorities for a National Strategy Chronic hepatitis B and associated liver diseases, including.
ALAN FRANCISCUS EXECUTIVE DIRECTOR, HEPATITIS C SUPPORT PROJECT EDITOR-IN-CHIEF, HCV ADVOCATE WEBSITE JOIN ME ON TWITTER & FACEBOOK – HCVADVOCATE BLOG:
SIGN Rapid Assessment Survey Northern Areas, Pakistan Lubna Samad, MRCS, FCPS Pediatric Surgeon National Institute of Child Health.
Ongoing Implementation of the National HIV/AIDS Strategy to Improve HIV Prevention and Care Grant Colfax, MD Office of National AIDS Policy International.
Wyoming Department of Health Communicable Diseases
VIRTUAL MEDZONE Your Resource for Hepatitis Related Innovative Medical Communication.
The State of ADAPs Review of the 2011 National ADAP Monitoring Project Annual Report and Update on the ADAP Crisis Britten Pund National Alliance of State.
Dispelling HCV Myths February 2014.
Co-occurring Challenges: Leveraging ADAP and ACA to Address Hepatitis C and Substance Use Disorders Daniel Raymond Policy Director Harm Reduction Coalition.
Worktext p = = = =
Sarah Weninger Adult Viral Hepatitis Prevention Coordinator Division of Disease Control Phone:
HEPATITIS MOBILE TEAM News Tools of screening viral hepatitis in real life: the french model of care André-Jean REMY (1,2), Hugues WENGER (1), Hakim BOUCKHIRA.
Proportions Round One 2) x + 3 = 15 Answers 2.) x + 3 = 15 X=12 21.
TUPDD0101:W ILL A MULTIPLEX ASSAY DETECT NEW INFECTIONS OF HIV, S YP, H EP C AND B IN U RBAN I NDIA ? 1.Detect New infections of HIV, Hepatitis C, syphilis.
Hepatitis. Hepatitis is an inflammation of the liver. Hepatitis is caused by several types of viruses as well as drug and chemical toxicity.
Hepatitis C A Growing Problem of Pakistan. Group Members Zoya Imran Mariam Archer Nawal Nawaz Sidra Tul Muntaha.
Blood Tests (“Labs”) 1. “Labs” Regular blood tests are a crucial part of HIV health care. They are often referred to as “bloods” or “labs” Several important.
CLICK THE NUMBERS IN SEQUENCE
Evaluation of Hepatitis B surveillance system in Armenia, 2014 AUTHORS Karine Gevorgyan Lusine Paronyan Shushan Sargsyan Artavazd Vanyan NCDC, Armenia.
Seroprevalance of Hepatitis C in Turkey (%) (Anti-HCV positivity in donors) Adana (n:8310) Antalya (n:16.410) Bursa (n:16.512) Erzurum (n:24.870) İstanbul.
CLICK ON THE CLOCK What’s the time? It’s half past nine. GREAT TRY AGAIN It’s nine o’clock. It’s a quarter to twelve.
Karyn Kaplan Thai AIDS Treatment Action Group (TTAG)
HBV. Overview of the Epidemiology of Hepatotropic Viruses.
Date of download: 7/10/2016 From: Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label,
Economic Impact of Eliminating HCV H. Razavi April 13, 2016.
Role of Ministry of Health and Medical Education in management and control of Hepatitis C 2016/07/13.
PI project: Hepatitis B prophylaxis in patients with malignancies
HIV Care Continuum Ryan White Program - Miami-Dade County
What is Hep C Dave Stafford.
Where Are We on the Path to Elimination of Chronic Hepatitis C?
In The Name of God.
Acute HCV genotype 1 infection * No HBV or HIV co-infection
Scaling up Hepatitis C diagnosis and treatment in Punjab
The typical course of acute and chronic hepatitis C
Viral Load (copies/ml)
MICROBIOLOGY PRACTICAL
Treating Hep C with Novel Agents
Uninsured Adults and Those with Coverage Gaps Reported Cost-Related Access Problems at Higher Rates Than Did Those Continuously Insured Percent of adults.
Expanding the Universe of Viral Hepatitis Treaters
Chronic Hepatitis C Therapy: Changing the Rules of Duration
Jeffrey J. Germer, BS, Nizar N. Zein, MD  Mayo Clinic Proceedings 
Performance Characteristics of a Quantitative Hepatitis C Virus RNA Assay Using COBAS AmpliPrep Total Nucleic Acid Isolation and COBAS TaqMan Hepatitis.
More Than Treatment.
بسم الله الرحمن الرحیم.
Women in the U.S. Report Highest Rates of Not Getting Needed Care Because of Cost Percent of women ages 19–64 who experienced any access problem because.
NUMBERS one two three four five six seven eight
Hepatitis C: After the Diagnosis
Development and Validation of a Template-Independent Next-Generation Sequencing Assay for Detecting Low-Level Resistance-Associated Variants of Hepatitis.
Carolina Family Health Centers In+care 04-Viral Load Suppression
More Than One-Third of Women in the U. S. Skip Care Because of Cost vs
Volume 138, Issue 1, Pages e2 (January 2010)
CLICK THE NUMBERS IN SEQUENCE
Chronic Hepatitis C Therapy: Changing the Rules of Duration
No HBV or HIV co-infection
Total number of screenings in 2016
Timothy P. Sheahan, Charles M. Rice  Gastroenterology 
CLICK THE NUMBERS IN SEQUENCE
Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis.
Etanercept therapy in two patients with psoriasis and concomitant hepatitis C  Clara De Simone, MD, Andrea Paradisi, MD, Rodolfo Capizzi, MD, Angelo Carbone,
Pei-Yuan Su,Yu-Chun Hsu,Shun-Sheng Wu,Wei-Wen Su,Maw-Soan Soon
Presentation transcript:

ADAP and Hepatitis B Coverage  In June 2012, 29 ADAPs covered at least one of the medications for HBV on their formularies.  ADAPs filled 325 hepatitis B treatment prescriptions for 314 clients in June In FY2011, ADAPs filled 3,473 hepatitis B prescriptions.

ADAP and Hepatitis C Coverage  In June 2012, 27 ADAPs covered at least one of the medications for HCV on their formularies.  ADAPs filled 336 hepatitis C treatment prescriptions for 242 clients in June  Ten ADAPs reported providing coverage for hepatitis C diagnostics in June 2012, including: –Nine ADAPs covered HCV screening. –Nine ADAPs covered qualitative HCV RNA. –Ten ADAPs covered quantitative viral load. –Seven ADAPs covered HCV genotype.

ADAP and Hepatitis Vaccine Coverage  Twenty-five ADAPs covered the hepatitis A and B combination vaccine in June  Twenty-five ADAPs covered the hepatitis A vaccine in June  Twenty-five ADAPs covered the hepatitis B vaccine in June 2012.